Pancreatic carcinoma
Immuneering’s Pancreatic Cancer Therapy Shows Promising Results in Phase 2a Trial, Stock Surges 55%
Immuneering, IMM-1-104, Pancreatic Cancer, Phase 2a Trial, MEK Inhibitor, Cancer Therapy, Clinical Trial Results, Stock Surge
FDA Grants Accelerated Approval to Merus’ Bizengri for NRG1+ Lung and Pancreatic Cancers
Bizengri, NRG1+ cancers, FDA accelerated approval, lung cancer, pancreatic cancer, zenocutuzumab-zbco, Merus N.V.
Alligator Bioscience Cuts 70% of Workforce to Address Financial Challenges and Refocus on Pancreatic Cancer Research
Alligator Bioscience, layoffs, cost-cutting, pancreatic cancer research, financial constraints, biotech industry
FDA Delays Decision on Merus’ Zenocutuzumab for NRG1+ Lung and Pancreatic Cancer
Zenocutuzumab, NRG1+ cancer, FDA delay, Merus, lung cancer, pancreatic cancer, bispecific antibody.
Revolution Medicines Advances in Pancreatic Cancer Treatment with RMC-6236 and RMC-9805
Revolution Medicines, RMC-6236, RMC-9805, pancreatic cancer, RAS inhibitors, targeted therapies, clinical trials
FibroGen Lays Off 75% of US Staff After Cancer Drug Fails in Two Phase III Trials
FibroGen, cancer drug, layoffs, Phase III trials, pamrevlumab, oncology, pancreatic cancer, chemotherapy, anaemia therapy, roxadustat, Astellas, AstraZeneca
FibroGen to Shrink US Workforce by 75% Following More Late-Stage Fails
FibroGen, workforce reduction, pamrevlumab, clinical trials, biotech layoffs, pancreatic cancer drug